TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA
We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients' needs, now and in the future.
We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities consists of approximately 34,000 employees across 57 markets.
We operate our business through three segments: United States, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes biosimilars and over-the-counter ("OTC") products, as well as innovative medicines. This structure enables strong alignment and integration between operations, commercial regions, R&D, and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.27B | $21.85B | $21.90B |
| Cost of revenue | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B | $8.93B | $9.35B | $9.97B | $11.24B | $10.25B |
| Gross profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B | $7.73B | $7.54B | $8.30B | $10.62B | $11.65B |
| R&D | — | — | — | $98.0M | — | — | — | $114.0M | $175.0M | $422.0M |
| SG&A | $1.29B | $1.16B | $1.16B | $1.18B | $1.10B | $1.17B | $1.19B | $1.30B | $1.45B | $1.39B |
| Operating income | $2.16B | -$303.0M | $433.0M | -$2.20B | $1.72B | -$3.57B | -$443.0M | -$1.64B | -$17.48B | $2.15B |
| Interest expense | $916.0M | $1.00B | $1.03B | $930.0M | $891.0M | $901.0M | $822.0M | $920.0M | $875.0M | $546.0M |
| Pre-tax income | $1.22B | -$1.28B | -$624.0M | -$3.16B | $658.0M | -$4.41B | -$1.26B | -$2.60B | -$18.38B | $824.0M |
| Income tax | $180.0M | $676.0M | $7.0M | $643.0M | $211.0M | $168.0M | $278.0M | $195.0M | $1.93B | $521.0M |
| Net income | $1.41B | -$1.64B | -$559.0M | -$2.45B | $417.0M | -$3.99B | -$999.0M | -$2.15B | -$16.27B | $329.0M |
| EPS, basic | 1.23 | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 | -0.91 | -2.35 | -16.26 | 0.07 |
| EPS, diluted | 1.21 | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 | -0.91 | -2.35 | -16.26 | 0.07 |
| Shares, diluted (wtd. avg.) | $1.16B | $1.13B | $1.12B | $1.11B | $1.11B | $1.09B | $1.09B | $1.02B | $1.02B | $961 |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.56B | $3.30B | $3.23B | $2.83B | $2.20B | $2.18B | $1.98B | $1.78B | $963.0M | $988.0M |
| Receivables | $3.71B | $3.06B | $3.41B | $3.70B | $4.53B | $4.58B | $5.68B | $5.82B | $7.13B | — |
| Inventory | $3.18B | $3.01B | $4.02B | $3.83B | $3.82B | $4.40B | $4.42B | $4.73B | $4.92B | — |
| Total current assets | $13.95B | $12.55B | $12.48B | $12.05B | $12.57B | $13.01B | $13.46B | $13.79B | $15.38B | — |
| Property, plant and equipment | $4.08B | $4.58B | $5.75B | $5.74B | $5.98B | $6.30B | $6.44B | $6.87B | $7.67B | — |
| Goodwill | $16.00B | $15.15B | $17.18B | $17.18B | $17.63B | $20.62B | $24.85B | $24.92B | $28.41B | $44.41B |
| Other intangibles | $3.78B | $4.42B | $5.39B | $6.27B | $7.47B | $8.92B | $11.23B | $14.01B | $17.64B | — |
| Total assets | $40.75B | $39.33B | $43.48B | $45.93B | $47.67B | $50.64B | $57.47B | $60.68B | $70.61B | — |
| Accounts payable | $225.0M | $158.0M | $108.0M | — | — | — | $1.72B | $1.85B | $2.07B | — |
| Short-term debt | $1.80B | $1.76B | $1.65B | $2.09B | $1.40B | $2.67B | $1.83B | $1.70B | $2.88B | — |
| Total current liabilities | $13.46B | $12.80B | $12.25B | $11.47B | $11.03B | $13.16B | $13.67B | $14.32B | $17.92B | — |
| Total liabilities | $32.83B | $33.61B | $35.35B | $36.12B | $36.42B | $39.58B | $42.41B | $44.89B | $51.87B | — |
| Retained earnings | -$13.76B | -$15.17B | -$13.53B | -$11.73B | -$10.53B | -$10.95B | -$6.96B | -$5.96B | -$3.80B | — |
| Total equity | $7.91B | $5.37B | $8.13B | $8.60B | $11.24B | $11.06B | $15.06B | $15.79B | $18.75B | $34.99B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.65B | $1.25B | $1.37B | $1.59B | $798.0M | $1.22B | $748.0M | $2.45B | $2.23B | $3.89B |
| Depreciation and amortisation | $421.0M | $471.0M | $537.0M | $576.0M | $528.0M | $537.0M | $609.0M | $676.0M | $632.0M | $501.0M |
| Stock-based compensation | $157.0M | $123.0M | $121.0M | $124.0M | $119.0M | $129.0M | $119.0M | $155.0M | $133.0M | $124.0M |
| Capital expenditure | $501.0M | $498.0M | $526.0M | $548.0M | $562.0M | $578.0M | $525.0M | $651.0M | $874.0M | $901.0M |
| Investing cash flow | $737.0M | $792.0M | $968.0M | $656.0M | $1.52B | $863.0M | $1.35B | $1.87B | $3.45B | -$34.41B |
| Financing cash flow | -$2.15B | -$1.79B | -$1.91B | -$1.49B | -$2.17B | -$1.89B | -$1.93B | -$3.35B | -$5.75B | $25.22B |
| Dividends paid | — | — | — | — | — | — | — | $12.0M | $901.0M | $1.30B |
| Buybacks | — | — | — | — | — | $1.0M | $6.0M | $4.0M | $0 | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-034532.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |